Αποτελέσματα Αναζήτησης
15 Ιαν 2024 · People who have interstitial lung disease along with systemic sclerosis are much more likely to die from disease complications than people who do not have lung disease. Around 80% to 90% are alive five years after being diagnosed with interstitial lung disease from systemic sclerosis.
22 Μαΐ 2020 · This review summarizes morbidity and mortality outcomes in systemic sclerosis-related interstitial lung disease patients from high-quality observational and interventional studies over the last 50 years.
Similarly, the prognostic value of lung biopsy in patients with SSc-associated ILD is of limited value whereas assessment of clinical severity and lung function impairment are better predictors of outcome.
15 Ιουν 2024 · When scleroderma affects the heart or lungs, it can cause shortness of breath, decreased exercise tolerance and dizziness. Scleroderma can cause scarring in the lung tissues that may result in increasing shortness of breath over time.
The key elements of scleroderma lung disease involve 1) inflammation (potentially treatable); 2) lung scarring (not reversible but potentially preventable); and 3) blood vessel injury (treatable – see Pulmonary Hypertension).
8 Φεβ 2024 · Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) that is often progressive and has a poor prognosis . SSc-associated ILD consists of various histopathologic subtypes, most commonly nonspecific interstitial pneumonitis and usual interstitial pneumonitis.
Pulmonary involvement in systemic sclerosis In scleroderma, the two most common types of direct pulmonary involvement are ILD and PH, which together account for 60% of SSc-related deaths [2].
